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Purpose: Disease state may contribute to alteration in drug pharmacokinetics. The purpose of this study was 
to determine the effect of non-insulin dependent diabetes mellitus (NIDDM) on the pharmacokinetics of 
glipizide. 
Methods: An open, single-dose, parallel design was applied to the study. Glipizide tablet (5 mg) was 
administered to healthy and diabetic human volunteers after over-night fast. Blood samples were collected, 
centrifuged and the plasma assayed using a sensitive and validated reverse phase high performance liquid 
chromatography (RP-HPLC) method. Various pharmacokinetic parameters were computed from the data 
obtained. 
Results: The AUC0-∞ values for healthy and diabetic volunteers was 1878 ± 195 and 1723 ± 138 ng.h/ml, 
respectively; these values were not significantly different (p > 0.05). The t1/2 for healthy volunteers was 3.04 ± 
0.27 h while that for diabetic subjects was 2.98 ± 0.16 h. Clearance for healthy and diabetic volunteers was 
0.59±0.06 and 0.64±0.05 ml/min/kg, respectively. These and other pharmacokinetic parameters assessed 
were not significantly different between healthy and diabetic volunteers (p > 0.05). 
Conclusion: Although glipizide showed slightly more rapid clearance from the body of diabetic volunteers 
than from healthy volunteers, this difference, like those for other pharmacokinetic parameters, was not 
significant (p > 0.05).   
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INTRODUCTION 
 
Diabetes mellitus is not a single disease but a 
group of clinically heterogeneous disorders 
with glucose intolerance in common. It 
encompasses many causally unrelated 
diseases and includes many different 
etiologies of disturbed glucose tolerance 
[1,2]. The term, diabetes mellitus, is used to 
describe a syndrome characterized by 
chronic hyperglycemia and other 
disturbances of carbohydrate, fat and protein 
metabolism. Millions of people all around the 
world are suffering from diabetes mellitus 
with 5 – 10 % of them suffering from type I 
diabetes mellitus (otherwise known as 
insulin-dependent diabetes mellitus, IDDM) 
and 90 – 95 % of them from type II diabetes 
mellitus (also known as non-insulin 
dependent diabetes mellitus, NIDDM). While 
the most suitable and commonly available 
treatment for type I diabetes mellitus is 
insulin, there are number of oral drug 
therapies available for the treatment of type II 
diabetes, e.g., biguanides and 
sulphonylureas.  
 
The present study is essentially focused on 
glipizide which is a second generation 
sulfonylurea [3]. It contains not less than 98 
% and not more than the equivalent of 102 % 
of I-cyclohexyl-3-{4-((2-(5-methylpyrazine-2-
carboxamido) ethyl)) benze-nesulphonyl} 
urea, calculated with reference to the dried 
substance [4]. Glipizide is widely used in the 
management of type II diabetes and, like 
other sulphonylureas, its overall mechanism 
of action is unknown. However, its 
predominant mechanism of action appears to 
be by increasing the secretion of insulin from 
the islets of Langerhans in both normal and 
diabetic humans and by decreasing the 
metabolic clearance rate of insulin [5]. Other 
proposed mechanisms include, increasing 
sensitivity of peripheral tissues to insulin 
effects, increasing the number of insulin 
receptors and increasing binding to and/or 
affinity of insulin for its receptors. Glipizide is 
almost completely absorbed after oral 
administration [6] but its absorption is 
delayed when taken with food.  Therefore, 
glipizide is most effective when given at least 
30 min before meals both in normal and 
diseased state [7]. Its initial dose is 5 mg 
once or twice daily with a maximum daily 
divided dose of 40 mg [6,8]. Peak blood 
levels are usually reached within 2 to 4 h 
after oral administration with a half-life of 3 to 
7 h and duration of action of about 10 h in 
healthy human subjects [9]. Glipizide has an 
apparent volume of distribution of 0.13 l/kg in 
diabetic patients [10] and is contraindicated 
for patients with severe liver and renal 
disorders [3]. The most commonly 
encountered side effects include nausea, 
vomiting, headache, weakness, skin rashes, 
aplastic anemia, visual disturbances, 
impaired hepatic function, hypoglycemia and 
coma [6,11] . 
 
The objective of this study was to obtain 
pharmacokinetic data for glipizide in healthy 
and diabetic human volunteers with a view to 
ascertaining if there was pharmacokinetic 







This study was an open, single-dose, parallel 
design. Twelve elderly diabetic and twelve 
elderly healthy human male volunteers (see 
Table 1) were included in the study. All 
subjects signed a written informed consent 
form before commencement of the study. The 
Pharmacy Ethical Committee of Faculty of 
Pharmacy, The Islamia University of 
Bahawalpur approved the study protocol for 
the human experiments.  Each volunteer 
received a single tablet dose of glipizide 5mg 
(Minidiab®, Pharmacia & Upjohn, Pakistan) 
orally at about 8:00am, thirty minutes before 
breakfast [9,10,12]. The tablets were 
administered with 200 ml of water and total 
water intake did not exceed 1500 ml during 
the 12 h study period. The subjects remained 
seated either on a bed or a chair for the next 
4 h. Standard lunch and dinner, not 
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exceeding 2000 kcal, were served 5 and 12 
h, respectively, after taking the tablet [9]. 
During the study period, the volunteers were 
constantly monitored by a physician in the 
Bioequivalence Sampling Room, Faculty of 
Pharmacy and Alternative Medicine, The 
Islamia University of Bahawalpur, Pakistan. 
 
Table 1: Patient demographic parameters and 






Age (years) 50.8 ± 3.5 49.6 ±2.8 
Weight (kg) 82.0 ± 3.2 80.3 ± 5.9 
Glucose (mg/dl) 94.7 ± 6.68 237.0 ± 17.3 
Albumin (g/dl) 4.21± 0.19 4.10 ± 0.08 
Creatinine (mg/dl) 1.08  ± 0.10 0.98 ± 0.11 
 
Selection criteria for volunteers 
           
Healthy volunteers: Human subjects with 
good health as determined by medical 
history, physical examination and laboratory 
data (hematology, serum chemistry, 
urinalysis, creatinine), and having age and 
weight ranging from 45 - 55 years and 70 - 90 
kg, respectively, were included in the study. 
Persons, who on physical examination 
showed signs suggesting abnormality of any 
organ system, or suffering from any infection 
or had any clinically significant abnormal 
laboratory values, were also excluded from 
the study. Volunteers with a known history of 
hyperglycaemia and hypoglycaemia were 
similarly excluded from the study. 
Furthermore, volunteers who had donated 
blood or suffered blood loss of > 200 ml in 
the four weeks preceding the screening were 
not enrolled in the study.  So also were 
persons having any history of alcohol or drug 
dependency or drug abuse, known allergy to 
sulfa drugs, congestive heart failure, 
pulmonary disease, renal insufficiency, use of 
tobacco products in last 2 years, or are using 
any medication which may act as inducer or 
inhibitor of hepatic enzymes [13].  
 
Diabetic volunteers: The inclusion and 
exclusion criteria of diabetic volunteers were 
similar to those for healthy volunteers except 
that fasting blood glucose level must be > 
130 mg/dl. Only those patients who 
maintained a fasting blood glucose level over 
130 mg/dl on prescribed diet and those who 
were without complication of diabetes 
mellitus were included in the study. Age and 
weight ranges were the same as for healthy 
volunteers. Patients  having  a history  of  
insulin  therapy  were  also  excluded  from 




A 20-gauge venous canula was inserted into 
the forearm of the volunteers for collection of 
blood samples. Blood samples were collected 
just before drug administration (zero time) 
and then at  0.5, 1.0, 1.5,   2.0, 2.5, 3.0, 3.5, 
4.0, 5.0, 6.0, 8.0, 10 and 12 h after 
administration of  glipizide tablet both for  
healthy and diabetic volunteers [9]. Blood (3 
ml) was collected in heparinized tubes, 
centrifuged and the plasma separated was 
stored frozen at -20 
0
C until analysed [14].  
 
HPLC analysis of glipizide 
 
Mobile phase: The mobile phase consisted 
of acetonitrile : 0.01M potassium di-hydrogen 
phosphate buffer (pH 3.5) in a ratio of 35 : 65 
[15]
 
which was degassed by sonication. It 
was eluted at a flow rate of 1.5 ml/min and 
the effluent was monitored at a wavelength of 
275 nm. Run time for each injection was 20 
min. 
 
Standard solutions: An initial stock solution 
of glipizide was prepared by dissolving 100 
mg of the drug in 100 ml of methanol: 
dichloromethane mixture (10 : 90). Standard 
solutions were obtained by diluting the initial 
stock solution with mobile phase [16] to give 
drug concentrations in the range of 0 - 1500 
ng/ml. The solutions were stable for 3 to 4 
months when stored at 4 
0
C, protected from 
light. 
 
Standard curve: A standard curve 
encompassing the anticipated range of 
plasma glipizide concentration was 
constructed. Blank plasma (500 µL) was 
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spiked with glipizide drug solutions to give 
concentrations of 50, 100, 200, 400, 800, 
1000, 1200, 1400  and 1600 ng/ml in a 10 ml 
glass centrifuge tube [16] followed by the 
addition of 1 ml of 0.05M HCl [14] and 
vortexed for 45 s.  It was extracted with 3 ml 
of toluene [14]
  
by vortexing for 45 s, and then 
centrifuged at 4000 rpm for 15 min.  The 
tubes were allowed to stand for 10 min and 
the clear supernatant was transferred to 
another glass tube and concentrated to 
dryness with a sample concentrator using 
nitrogen. The dry residue was reconstituted 
by vortexing with 75 µL of mobile phase and 
20 µl of it was injected into the 




Plasma samples (500 µL) obtained from 
healthy and diabetic volunteers containing 
glipizide were taken in 10 ml centrifuge tubes 
and 1 ml of 0.05M HCl was added. The 
samples were then treated as described 
above for spiked plasma used in preparing 




Pharmacokinetic analysis was performed 
using the non-compartmental method of 
analysis with Microsoft Excel 2003. The 
parameters, Cmax (maximum plasma 
concentration) and tmax (time to reach 
maximum plasma concentration), were 
determined from the concentration versus 
time curve. The area under the plasma 
concentration - time curve (AUC) was 
calculated by the trapezoidal rule.  Statistical 
analysis was carried out with Statistical 
Package for Social Sciences, version 15 
(SPSS Inc, USA). Descriptive statistics was 
adopted to summarize the data and Mann-
Whitney-U Test was applied as inferential 
statistics to observe association between 
various variables among the two groups. A p 





The pharmacokinetic data are listed in Table 
2. The value of Cmax was 465 ± 60 and 472 ± 
56 ng/ml for healthy and diabetic volunteers, 
respectively, while that of Tmax was 2.00 ± 
0.06 and 2.04 ± 0.74 h for healthy and 
diabetic subjects, respectively. AUC0-∞ for 
healthy and diabetic subjects was 1878 ± 195 
and 1723 ± 138 ng h/ml, respectively. On the 
other hand, the AUMC0-∞ (area under the 
mean curve) was 10169 ± 1467 and 9510 ± 
658 ng.h
2
/ml for healthy and diabetic 
volunteers, respectively. Mean resident time 
(MRT) for healthy volunteers was 5.24 ± 0.31 
and for diabetic volunteers 5.63 ± 2.86 h. The 
value of Ke (elimination rate constant) for 
healthy and diabetic volunteers was 0.25 ± 
0.02 and 0.24 ± 0.01 h
-1
, respectively, while 
t1/2 (half life) for healthy and diabetic subjects 
was 3.04 ± 0.27 and 2.98 ± 0.16 h, 
respectively. Volume of distribution (Vd) for 
healthy volunteers was 0.15 ± 0.01 L and 
0.17 ± 0.02 L/kg for diabetic volunteers while 
clearance (Cl) for healthy and diabetic 
volunteers was 0.59 ± 0.06 and 0.64 ± 0.05 
ml/min/kg, respectively. For all the 
parameters, no statistical significance was 
found between healthy and diabetic 




This study was aimed at determining whether 
there is any variability in glipizide 
pharmacokinetic in the diseased state. Few 
studies are available in the literature have 
addressed this aspect of glipizide 
pharmacokinetics. Based on the results 
obtained, it is evident that all pharmacokinetic 
parameters did not show statistical difference 
between normal and diseased (diabetics) 
subjects.  
 
The pharmacokinetics of a drug relates to its 
absorption, distribution, metabolism and 
excretion processes within the body. 
Variability in any of these processes will 
modify the target site concentration and its 
pharmacological effects. Physiological, path- 
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Table 2: Pharmacokinetic parameters (mean ± SEM) of glipizide (5 mg) administered orally to healthy and 
diabetic human volunteers  
 
Parameter 
Healthy  volunteers 
(Mean ± SEM) 
Diabetic volunteers 
(Mean ± SEM) 
P values for 
Mann-Whitney 
Test 
C max (ng/ml) 465 ± 60.16 472 ± 55.53
 
 0.64* 
tmax (h) 2 ± 0.06
 





/ml) 1878 ± 195.140
 





/ml) 10168.79 ± 1467.14 9510.22 ± 658.43 0.86* 
MRT (h) 5.24 ± 0.31
 





) 0.25 ±  0.02
 
 0.24 ± 0.01
 
 0.77* 
t1/2 (h) 3.04 ± 0.27
 
 2.98 ± 0.16
 
 0.75* 
Vd (L/Kg) 0.15 ±  0.01
 
 0.17 ± 0.02
 
 0.70* 
Cl (ml/min/kg) 0.59 ± 0.06
 




* No statistically significant difference at p < 0.05  between human and diabetic volunteers 
 
ological, genetic and/or pharmacological 
factors may contribute to these variations 
[17]. Any disease state that affects and 
changes the pathophysiologic condition of 
organs (especially liver and kidneys) may 
cause a significant variability in distribution, 
metabolism and excretion of drugs. 
Pathophysiological states of different organs 
are estimated by serum indicators, for 
example, serum albumin and creatinine 
levels.   
 
The baseline serum chemistry (serum 
albumin and creatinine levels) of diabetic 
volunteers did not demonstrate any major 
differences from that of healthy volunteers. 
The small but insignificant differences 
observed indicate that diabetes at this stage 
had not altered the functions of major organs 
(liver and kidneys). As a result no significant 
differences in pharmacokinetics of glipizide 
were observed in the present study.  
 
Although AUC and half life values showed a 
trend that appears to show that they were 
lower in diabetic volunteers, however, these 
pharmacokinetic differences are of less 
clinical importance. The plots in Fig 1 confirm 
the similarity of glipizide pharmacokinetics in 
healthy and human subjects. 
 
A close related study by Kradjan et al [13], 
which investigated the effect of age and 
disease on glipizide pharmacokinetics also 
reported insignificant differences with respect 
to these parameters. Several other studies 
[9,10,12,15,18-21] conducted on either 
healthy or diabetic human volunteers have 
































Fig. 1: Mean plasma concentration vs. time profile 
of orally administered glipizide (5 mg) in healthy 




The study showed that at an orally 
administered dose of 5 mg, glipizide kinetics 
is not significantly different in healthy and 
diabetic subjects. Therefore, data obtained 
using healthy volunteers can be extended to 
diabetics. The observed minor variation in 
pharmacokinetics is of less clinical 
importance. Glipizide could be administered 
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without adjusting the dosage and dose 
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